HUE068584T2 - N-(Imidazo[1,2-b]piridazin-3-il)-1-ciklohexil-2H-indazol-5-karboxamid- és N-(pirazolo[1,5-]pirimidin-3-il)-1-ciklohexil-2H-indazol-5-karboxamid-származékok mint IRAK 4 inhibitorok asztma kezelésére - Google Patents

N-(Imidazo[1,2-b]piridazin-3-il)-1-ciklohexil-2H-indazol-5-karboxamid- és N-(pirazolo[1,5-]pirimidin-3-il)-1-ciklohexil-2H-indazol-5-karboxamid-származékok mint IRAK 4 inhibitorok asztma kezelésére

Info

Publication number
HUE068584T2
HUE068584T2 HUE21836097A HUE21836097A HUE068584T2 HU E068584 T2 HUE068584 T2 HU E068584T2 HU E21836097 A HUE21836097 A HU E21836097A HU E21836097 A HUE21836097 A HU E21836097A HU E068584 T2 HUE068584 T2 HU E068584T2
Authority
HU
Hungary
Prior art keywords
indazole
cyclohexyl
carboxamide
pyridazin
pyrazolo
Prior art date
Application number
HUE21836097A
Other languages
English (en)
Hungarian (hu)
Inventor
Ina Terstiege
Stefan Schiesser
Yafeng Xue
Hui-Fang Chang
Anna Ingrid Kristina Berggren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUE068584T2 publication Critical patent/HUE068584T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE21836097A 2020-12-10 2021-12-09 N-(Imidazo[1,2-b]piridazin-3-il)-1-ciklohexil-2H-indazol-5-karboxamid- és N-(pirazolo[1,5-]pirimidin-3-il)-1-ciklohexil-2H-indazol-5-karboxamid-származékok mint IRAK 4 inhibitorok asztma kezelésére HUE068584T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063199160P 2020-12-10 2020-12-10

Publications (1)

Publication Number Publication Date
HUE068584T2 true HUE068584T2 (hu) 2025-01-28

Family

ID=79230946

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21836097A HUE068584T2 (hu) 2020-12-10 2021-12-09 N-(Imidazo[1,2-b]piridazin-3-il)-1-ciklohexil-2H-indazol-5-karboxamid- és N-(pirazolo[1,5-]pirimidin-3-il)-1-ciklohexil-2H-indazol-5-karboxamid-származékok mint IRAK 4 inhibitorok asztma kezelésére

Country Status (33)

Country Link
US (3) US11866405B2 (cg-RX-API-DMAC7.html)
EP (1) EP4259632B1 (cg-RX-API-DMAC7.html)
JP (1) JP7749015B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118153A (cg-RX-API-DMAC7.html)
CN (1) CN116583285B (cg-RX-API-DMAC7.html)
AR (1) AR124303A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021395816B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203569A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001662A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007624A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230264A (cg-RX-API-DMAC7.html)
DK (1) DK4259632T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000119A (cg-RX-API-DMAC7.html)
EC (1) ECSP23050553A (cg-RX-API-DMAC7.html)
ES (1) ES2989489T3 (cg-RX-API-DMAC7.html)
FI (1) FI4259632T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241312T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068584T2 (cg-RX-API-DMAC7.html)
IL (1) IL303356B2 (cg-RX-API-DMAC7.html)
LT (1) LT4259632T (cg-RX-API-DMAC7.html)
MA (1) MA62535B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006816A (cg-RX-API-DMAC7.html)
PE (1) PE20240684A1 (cg-RX-API-DMAC7.html)
PL (1) PL4259632T3 (cg-RX-API-DMAC7.html)
PT (1) PT4259632T (cg-RX-API-DMAC7.html)
RS (1) RS66095B1 (cg-RX-API-DMAC7.html)
SI (1) SI4259632T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400417T1 (cg-RX-API-DMAC7.html)
TW (1) TWI902994B (cg-RX-API-DMAC7.html)
UA (1) UA130417C2 (cg-RX-API-DMAC7.html)
UY (1) UY39561A (cg-RX-API-DMAC7.html)
WO (1) WO2022122876A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306848B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152349A1 (en) * 2022-02-14 2023-08-17 Astrazeneca Ab Irak4 inhibitors
US20250326757A1 (en) * 2022-05-26 2025-10-23 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体
HUE029617T2 (en) 2010-12-20 2017-03-28 Merck Serono Sa Indazolyl triazole derivatives as IRAK inhibitors
BG111378A (bg) * 2013-01-14 2015-01-30 Николай Цветков Субституирани индазолови производни като in-vitro mao-b инхибитори
RU2665554C2 (ru) * 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
PL3536685T3 (pl) 2014-04-04 2022-05-16 Pfizer Inc. Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
CA2992406A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CN105503863A (zh) * 2015-12-11 2016-04-20 南京华威医药科技开发有限公司 新型抗肿瘤化合物
EP3394066A2 (en) 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
WO2017207386A1 (de) 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
JP2020524692A (ja) 2017-06-21 2020-08-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Irak4調節因子としてのベンゾフラン
CN110785418A (zh) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 作为irak4调节剂的异二氢吲哚酮衍生物
KR20220027196A (ko) 2019-06-27 2022-03-07 바이오젠 엠에이 인코포레이티드 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
CN114585609B (zh) 2019-06-27 2024-07-30 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途

Also Published As

Publication number Publication date
DK4259632T3 (da) 2024-10-21
UA130417C2 (uk) 2026-02-11
IL303356B1 (en) 2026-04-01
HRP20241312T1 (hr) 2024-12-20
LT4259632T (lt) 2024-10-10
EP4259632B1 (en) 2024-07-24
PE20240684A1 (es) 2024-04-10
PT4259632T (pt) 2024-10-24
CL2023001662A1 (es) 2024-01-12
JP7749015B2 (ja) 2025-10-03
KR20230118153A (ko) 2023-08-10
ES2989489T3 (es) 2024-11-26
AU2021395816B2 (en) 2024-04-04
WO2022122876A1 (en) 2022-06-16
AR124303A1 (es) 2023-03-15
US20220185817A1 (en) 2022-06-16
AU2021395816A9 (en) 2025-03-13
ZA202306848B (en) 2024-04-24
CN116583285A (zh) 2023-08-11
IL303356A (en) 2023-08-01
FI4259632T3 (fi) 2024-10-24
TW202237612A (zh) 2022-10-01
EP4259632A1 (en) 2023-10-18
UY39561A (es) 2022-06-30
US11866405B2 (en) 2024-01-09
MX2023006816A (es) 2023-06-21
RS66095B1 (sr) 2024-11-29
ECSP23050553A (es) 2023-08-31
US20240182479A1 (en) 2024-06-06
MA62535B1 (fr) 2024-11-29
CA3203569A1 (en) 2022-06-16
US20260092069A1 (en) 2026-04-02
CR20230264A (es) 2023-07-26
SI4259632T1 (sl) 2024-12-31
IL303356B2 (en) 2026-08-01
CO2023007624A2 (es) 2023-06-30
PL4259632T3 (pl) 2024-12-16
SMT202400417T1 (it) 2024-11-15
CN116583285B (zh) 2026-03-24
US12448385B2 (en) 2025-10-21
TWI902994B (zh) 2025-11-01
AU2021395816A1 (en) 2023-07-13
DOP2023000119A (es) 2023-07-09
JP2023552838A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
IL303356B1 (en) N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma
RU2412171C2 (ru) Новое соединение пиперазина и его применение в качестве ингибитора hcv полимеразы
CA3266687A1 (en) PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR CANCER TREATMENT
NZ599291A (en) Antimicrobial compounds and methods of making and using the same
MY146474A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
IL190061A0 (en) 5-amino-4-hydroxy-7-(imidazo[1,2-a]pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
IL186422A0 (en) Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
WO2007039740A3 (en) Preparation and use of tetrahydropyrrolo [3, 2-c] pyridin-4-one derivatives for treatment of obesity, psychiatric and neurological disorders
EP3856743A4 (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
IL272652B (en) A pentacyclic compound, the pharmaceutical compounds that make it up and their use for the treatment of Alzheimer's disease
MX362197B (es) Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
CA2342830A1 (en) 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
ZA202102974B (en) 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
EP4393924A4 (en) IMIDAZO[1,2-A]PYRAZINE OR PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVE AND USE THEREOF
MX2023005761A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
HK40103397A (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use
WO2006127574A3 (en) Method for the treatment of noise phobia in companion animals
HK40116553A (en) Polymorphic and salt forms of (ls,3s)-n-(5-(pentan-3-yl)pyrazolo[l,5-a]pyrimidin-7-yl)cyclopentane-l,3-diamine
HK40102603A (en) Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease
AU2023904024A0 (en) Use of selected (1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone compounds in the treatment of cardiovascular diseases
EP4436569A4 (en) POLYMORPHIC AND SALT FORMS OF (LS,3S))-N-(5-(PENTAN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)CYCLOPENTANE-L,3-DIAMINE
WO2024073282A3 (en) Heterocycles as modulators of nsd activity
CA3262884A1 (en) Pharmaceutically acceptable salt and polymorph of substituted pyrazolo[1,5-a]pyrimidin-7-amine derivative and use thereof